

ESMO 2022 Industry Satellite Symposium

Decision-Making Discussions: IO in advanced NSCLC (aNSCLC)

Monday, 12 September 2022 | 13:00-14:30 (CEST)

7.3.U - Urval Auditorium, Hall 7, Level 7.3, Paris Expo Porte de Versailles, Paris, France

13:00-13:10

Welcome and Introduction

Roy Herbst (Chair)

13:10-13:25

The role of biomarkers in selecting first-line therapy in aNSCLC

Roy Herbst

First-line therapy in aNSCLC - Clinical cases forum

13:25-13:45

A case with squamous histology

William Nassib William

13:45-14:05

A case of unresectable locally advanced NSCLC, ineligible for surgical resection or definitive chemoradiation

Benjamin Besse

14:05-14:25

A case with brain metastases at presentation

Florian Fuchs

14:25-14:30

Closing remarks

Roy Herbst



Roy Herbst (Chair)

Professor, Yale School of Medicine,
New Haven, USA



William Nassib William

Professor, BP Oncology Center,
São Paulo, Brazil



Benjamin Besse

Professor, Gustave Roussy Villejuif,
France



Florian Fuchs

Professor, Universitätsklinikum
Erlangen, Erlangen, Germany

This is not a CME program. This nonpromotional event sponsored by Sanofi and Regeneron will include discussion of investigational products and products that may not be approved by the regulatory agency in your own country.

MAT-GLB-2202645 v1.0
Approval Date: 06/2022

sanofi **REGENERON**